Case Report: Nasal Cavity Epithelial-Myoepithelial Carcinoma With High Fluoro-D-Glucose Uptake on Positron Emission Tomography/Computed Tomography

Jacques Dzuko Kamga, Jean-Christophe Leclere, Arnaud Uguen, Karim Amrane and Ronan Abgral

1 Department of Nuclear Medicine, University Hospital of Brest, Brest, France, 2 Department of Otorhinolaryngology, University Hospital of Brest, Brest, France, 3 Department of Pathology, University Hospital of Brest, Brest, France, 4 EA 3878 GETBO, IFR 148, Bretagne Loire University, Brest, France

Epithelial-myoepithelial carcinoma (EMC) is a rare malignant neoplasm arising most frequently in the salivary glands and exceptionally in the nasal cavity. EMC accounts for ~1–2% of salivary gland tumors. Even if the nodal and distant metastasis rates are low, tumor staging remains indicated. Here, the authors present the 2-deoxy-2-[18F]fluoro-D-glucose PET-CT (18F-FDG-PET/CT) study of a very rare case of biopsy-proven EMC of the left nasal cavity. This 18F-FDG-PET/CT was performed to stage this tumor and guide the therapeutic strategy due to an atypical high-grade presentation in immunohistochemistry. To our knowledge, this is the first case reporting such high 18F-FDG avidity of EMC of the nasal cavity in PET/CT.

Keywords: nasal cavity, high grade, high avidity, 18FDG-PET/CT, epithelial-myoepithelial carcinoma (EMC)

INTRODUCTION

Epithelial-myoepithelial carcinoma (EMC) is a rare malignant tumor, accounting for ~1% of all salivary gland tumors (1); it is localized mainly in the parotid and submaxillary glands (2). This carcinoma also rarely occurs in the nasal cavity (3). EMC is considered as a low to intermediate grade malignancy and is associated with 5- and 10-year overall survival rates of respectively 72.7 and 59.5% (4). Regional lymph node invasion and distant metastases are rare and occur in less than 5% of cases (4).

To date, 2-deoxy-2-[18F]fluoro-D-glucose (F-FDG) PET-CT (18F-FDG-PET/CT) is not recommended for the characterization of salivary gland tumors (differentiation between benign and malignant disease) but can be proposed for the staging assessment of histologically proven malignancy (5).

We report a very rare case of biopsy-proven high-grade EMC of the left nasal cavity with high 18F-FDG avidity in PET/CT.

CASE DESCRIPTION

A 66-year-old man without previous medical history was referred to our department to undergo a pre-therapeutic 18F-FDG-PET/CT for the staging of an EMC of the left nasal cavity discovered on
The left nasal cavity EMC was removed by endoscopic resection ([Figure 2] showed the nasal septum ([Figure 2A1], the lower left nasal turbinate ([Figure 2A2], and the tumor ([Figure 2A*]), and after debulking, the origins of the tumor were identified ([Figure 2B white arrows]) before proceeding with a septectomy ([Figure 2B1]) and a left medial maxillectomy ([Figure 2B2]) to obtain a complete resection with safety margins of 1 cm.

The histopathology analysis ([Figure 3]) of the resected tumor showed a biphasic tumor with small luminal ducts surrounded by myoepithelial abluminal cells ([Figure 3A: hematoxylin-eosin-saffron, ×20]) (7). The ki-67 immunohistochemistry proliferative index was about 50% ([Figure 3B: MIB1, ×20]). The immunohistochemistry analysis showed the epithelial phenotype of luminal cells ([Figure 3C: pan-keratin AE1/AE3, Figure 3D: epithelial membrane antigen-EMA, ×20]) and the myoepithelial phenotype of abluminal cells ([Figure 3E: smooth muscle actin, Figure 3F: vimentin, ×20]).

DISCUSSION

The reported tumor was located in the region of the intersinus maxillary septa and connected to the nasal septa by a tissue extension partitioning the left nasal cavity that corresponds to a rare presentation. Indeed, in a recent large population-based analysis, Gore et al. reported 468 cases of EMC in the United States from 1973 to 2014 and identified only six cases (1.3%) of tumors in the nasal cavity (4).

We found an atypical high 18F-FDG uptake (SUVmax = 8.9) over this lesion as EMC has been reported to show no significant 18F-FDG uptake on PET/CT which may be associated with its very common low-grade malignant potential (5, 8).

To our knowledge, this is the first case of EMC of the nasal cavity presenting such 18F-FDG avidity on PET/CT (8–10). Only Sharma et al. reported a case of 18F-FDG-positive EMC of the lacrimal sac incidentally highlighted on a PET/CT performed in a patient with colorectal cancer (11). Nevertheless, this 18F-FDG avidity could be explained by the high Ki-67 expression (50%) that was found in the immunohistochemistry analysis, classifying this tumor atypically in high grade. Ki-67 is a protein expressed in all phases of the cell cycle, except the G0-phase, therefore estimating the fraction of proliferative cells in tissues (12). Furthermore, the Ki-67 index and SUVmax value are well-known to be highly correlated in other head and neck cancers (13). Another approach based on sequential biphasic 18F-FDG-PET scanning protocol could have been used to distinguish benign and malignant lesions (14, 15).

Finally, although this presentation remains extremely rare, it probably increases the risk of locoregional or distant remote extension (16).

CONCLUSION

2-deoxy-2-[18F]fluoro-D-glucose PET-CT (FDG-PET/CT) might be an interesting tool for assessing remote extension of such rare presentation of EMC with high Ki-67 expression.
FIGURE 2 | Endoscopic examination before (A) and after (B) tumor debulking.

FIGURE 3 | Histopathology results. (A) hematoxylin-eosin-saffron, x20, (B) Ki-67 MIB1, x20, (C) pan-keratin AE1/AE3, x20, (D) epithelial membran antigen-EMA, x20, (E) smooth muscle actin, x20, and (F) vimentin, x20.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

All procedures performed in this study were in accordance with the Ethical Standards of the Institutional Research Committee on Human Experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Ethical review and approval were not required in accordance with the national and institutional requirements. The patient provided written informed consent.

AUTHOR CONTRIBUTIONS

RA and JDK are the guarantors of the manuscript and analyzed the imaging. KA and J-CL ensured the clinical follow-up of the patient. AU provided the histopathology. JDK, J-CL, AU, KA, and RA contributed to drawing up. All authors contributed to the article and approved the submitted version.
REFERENCES

1. Vázquez A, Patel TD, D’Aguiullo CM, Abdou Ry, Farver W, Baredes S, et al. Epithelial-myoepithelial carcinoma of the salivary glands: an analysis of 246 cases. Otolaryngol Head Neck Surg Off Am Acad Otolaryngol-Head Neck Surg. (2015) 153:569–74. doi: 10.1177/0194598815594788

2. Schuman TA, Kimple AI, Edgeryl CH, Ebert CS, Zanation AM, Thorp BD, et al. Sinonasal epithelial-myoepithelial carcinoma: report of a novel subsite and review of the literature. Allergy Rhinol Prog RI. (2018) 9:2152656718764229. doi: 10.1177/2152656718764229

3. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. (2012) 34:87–85. doi: 10.1002/hed.21830

4. Gore MR. Epithelial-myoepithelial carcinoma: a population-based survival analysis. BMC Ear Nose Throat Disord. (2018) 18:15. doi: 10.1186/s12901-018-0063-2

5. Salaün P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. (2020) 47:28–50. doi: 10.1007/s00259-019-04553-8

6. Querellou S, Keromnes N, Abgral R, Sassolas B, Le Roux PY, Cavarec MB, et al. Clinical and therapeutic impact of 18F-FDG PET/CT for patients with salivary gland malignancies. J Nucl Med Off Publ Soc Nucl Med. (2007) 48:240–6.

7. Nakaguro M, Nagao T. Epithelial-myoepithelial carcinoma. Surg Pathol Clin. (2011) 24(Suppl 2):S67–72. doi: 10.1016/j.breast.2015.07.017

8. Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast Edinb Scotl. (2015) 24(Suppl 2):567–72. doi: 10.1016/j.breast.2015.07.017

9. Meyer H-J, Gundermann P, Surow A. Associations between FDG-PET and Ki 67-index in head and neck cancer: a meta-analysis. Medicine. (2019) 98:e17472. doi: 10.1097/MD.0000000000017472

10. Pietrzak AK, Marszałek A, Kazmierska J, Kunikowska J, Golusimpi P, Suchorska WM, et al. Sequential delayed 18F-FDG PET/CT examinations in the pharynx. Sci Rep. (2020) 10:2910. doi: 10.1038/s41598-020-59832-4

11. Kubota K, Yokoyama K, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. Delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. (2004) 31:590–5. doi: 10.1007/s00259-003-1408-6

12. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. (2012) 34:87–85. doi: 10.1002/hed.21830

13. Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast Edinb Scotl. (2015) 24(Suppl 2):567–72. doi: 10.1016/j.breast.2015.07.017

14. Meyer H-J, Gundermann P, Surow A. Associations between FDG-PET and Ki 67-index in head and neck cancer: a meta-analysis. Medicine. (2019) 98:e17472. doi: 10.1097/MD.0000000000017472

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Dzuko Kamga, Leclere, Uguen, Amrane and Abgral. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.